联合检测vimentin和SFRP2甲基化在大肠癌筛查中的应用评价  

Colorectal cancer screening by detecting the methylation status of vimentin and SFRP2

作　　者：肖著军[1] 王新颖[1] 李丙生[2] 李钊[1] 马群英 朱伟思[1] 王国振[1] 林金凤[1] 许岸高[1,3] 

机构地区：[1]南方医科大学南方医院消化内科,510515 [2]惠州市第一人民医院,516003 [3]广东省惠州市医学研究所,516003

出　　处：《现代消化及介入诊疗》2014年第1期13-16,20,共5页Modern Interventional Diagnosis and Treatment in Gastroenterology

基　　金：广东省科技计划项目(2012B050600022;2010B031600098);广东省医学科学技术研究基金(WSTJJ20121203431003197608036514);惠州市科技计划项目(2013Y121;2013Y122)

摘　　要：目的评价在粪便样本中联合检测vimentin和SFRP2甲基化来筛查大肠癌的性能。方法搜集合格的新鲜粪便标本95例,其中40例大肠癌患者、25例进展期腺瘤患者和30例结肠镜阴性的正常人,应用甲基化特异性PCR(MSP)法检测vimentin和SFRP2甲基化状态,并与单个基因甲基化检测和粪隐血试验(FOBT)的诊断性能相比较是否有统计学差异。结果大肠癌组中vimentin和SFRP2甲基化阳性检出率分别为55.0%(22/40)和70.0%(28/40);进展期腺瘤组中为48.0%(12/25)和64.0%(16/25);正常对照组中为6.7%(2/30)和0(0/30)。在病例组中两基因联合检测的敏感性为83.1%(54/65),明显高于vimentin的52.3%(34/65)和SFRP2的67.7%(44/65),更要高于FOBT的27.7%(18/65)(均P<0.05)。而在正常对照组中两基因联合检测的特异性为93.3%(28/30),与vimentin的93.3%(28/30)和SFRP2的100%(30/30)以及FOBT的96.7%(29/30)相比均无明显差异(均P>0.05)。结论在大肠癌筛查中,联合检测粪便中vimentin和SFRP2基因甲基化状态明显优于单个基因和粪便潜血试验,具有潜在的应用价值。Objective To assess the diagnostic value of vimentin and SFRP2 methylation for colorectal cancer screening. Methods Ninety-five qualified stool samples from different subjects consisting of 40 col-orectal cancer patients, 25 advanced adenoma patients and 30 normal controls were collected. The methylation status of vimentin and SFRP2 in stool samples was detected by methylation-specific PCR （MSP）. Results The detection rates of vimentin in colorectal cancers, advanced adenomas and healthy controls were 55.0%（22/40）, 48.0%（12/25）, and 6.7%（2/30）;the detection rates of SFRP2 were 70.0%（28/40）,64.0%（16/25） and 0 （0/30）;and the detection rates of FOBT were 37.5%（15/40）, 12.0%（3/25） and 3.3%（1/30）, respectively. The diagnostic sensitivity with combination of the two markers was 83.1%（54/65） in patients, significantly higher than that of vimentin（ 52.3%, 34/65）, SFRP2（ 67.7%, 44/65）, and FOBT examination （27.7%, 18/65）（all P＆lt;0.05）, while no significant difference was found between the diagnostic specificity with combination of the two markers 93.3%（28/30） and that of vimentin 93.3%（28/30）, SFRP2 100%（30/30） and FOBT examination 96.7%（29/30） （all P ＆lt; 0.05）. Conclusions The combination of detecting vimentin and SFRP2 methylation has great performance for colorectal cancer screening.

关 键 词：VIMENTIN SFRP2 甲基化 大肠癌 VIMENTIN SFRP2 Methylation-specific PCR (MSP) 

分 类 号：R697.22[医药卫生—泌尿科学]